{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoantigen+DNA+Vaccine",
    "query": {
      "intervention": "Neoantigen DNA Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoantigen+DNA+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T13:28:57.504Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05456165",
      "title": "Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colonic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "GRT-C901",
          "type": "DRUG"
        },
        {
          "name": "GRT-R902",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gritstone bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-19",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-31",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456165"
    },
    {
      "nct_id": "NCT03122106",
      "title": "Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Cancer of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDS-IM Electrode Array System",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-01-05",
      "completion_date": "2022-08-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122106"
    },
    {
      "nct_id": "NCT07722741",
      "title": "Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCC"
      ],
      "interventions": [
        {
          "name": "GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Electroporation Device",
          "type": "DEVICE"
        },
        {
          "name": "INO-9012",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Geneos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-09",
      "completion_date": "2032-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 8,
      "location_summary": "Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07722741"
    },
    {
      "nct_id": "NCT03914872",
      "title": "Expanded Access Neoantigen Vaccine in Solid Tumors",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Neoantigen DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Integrated electroporation device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03914872"
    },
    {
      "nct_id": "NCT05743595",
      "title": "Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unmethylated Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Personalized Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDS-IM v 2.0 electroporation device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2023-10-27",
      "completion_date": "2029-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743595"
    },
    {
      "nct_id": "NCT04397003",
      "title": "Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "TDS-IM v2.0 Device",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-03-30",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04397003"
    },
    {
      "nct_id": "NCT03199040",
      "title": "Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "TNBC - Triple-Negative Breast Cancer",
        "Triple-negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TDS-IM system (Inchor Medical Systems)",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2019-07-23",
      "completion_date": "2023-05-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199040"
    },
    {
      "nct_id": "NCT03988283",
      "title": "Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Recurrent Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Papivax Biotech TDS-IM v2.0",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 7,
      "start_date": "2024-10-02",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988283"
    },
    {
      "nct_id": "NCT04015700",
      "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics",
          "type": "DEVICE"
        },
        {
          "name": "Plasmid encoded IL-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-07-14",
      "completion_date": "2027-09-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04015700"
    },
    {
      "nct_id": "NCT03532217",
      "title": "Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hormone-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PROSTVAC-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PROSTVAC-F",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TriGrid Delivery System",
          "type": "DEVICE"
        },
        {
          "name": "Tumor biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral blood",
          "type": "PROCEDURE"
        },
        {
          "name": "Fecal samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2018-09-14",
      "completion_date": "2022-07-25",
      "has_results": false,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-09-26T13:28:57.504Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03532217"
    }
  ]
}